ArticleEuropean journal of medical research2026
H1FX as a novel biomarker linking pan-apoptosis to immune dysregulation in allergic rhinitis.
Article in European journal of medical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundAllergic rhinitis (AR), a major subtype of rhinitis, is characterized by dysregulated apoptosis in the nasal mucosa, a process intrinsically correlated with its inflammatory pathology. The aim of this study was to identify pan-apoptosis-related genes with diagnostic and therapeutic relevance in AR.
methodsWe analyzed AR-related datasets (GSE75011 and GSE50223) from Gene expression Omnibus (GEO) database. Differentially expressed genes (DEGs) from GSE75011 were intersected with pan-apoptosis-related genes identified by WGCNA. Biomarkers closely associated with AR progression were screened applying LASSO and Recursive Feature Elimination (RFE). Functional enrichment was assessed via GSEA, and single-sample GSEA (ssGSEA) was utilized to analyze the association between immune cell infiltration and the biomarkers. In vitro assays were carried out to further elucidate the role of H1FX in an AR model.
resultsDEGs were mainly enriched in IL-17 signaling pathway and MAPK signaling pathway. H1FX was identified as a key pan-apoptosis-related biomarker, with an AUC > 0.7 in ROC analysis. GSEA revealed differential enrichment of VEGF signaling pathway, MAPK signaling pathway, and Spliceosome and HALLMARK_G2M_CHECKPOINT between high and low expression groups of H1FX. ssGSEA analysis showed that H1FX expression was positively linked to Activated B cells, Central memory CD4 T cells, and significantly negatively correlated with Activated CD4 T cells in AR. Cellular assays confirmed that H1FX regulated proliferation and apoptosis in the AR model.
conclusionIntegrating computational analyses and experimental validation, we identified H1FX as a pivotal regulator of pan-apoptosis and inflammatory responses in AR, highlighting its potential as a diagnostic biomarker and therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.